Bryn Mawr Trust CO Annovis Bio, Inc. Put Options Transaction History
Bryn Mawr Trust CO
- $5.44 Billion
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ANVS
# of Institutions
49Shares Held
1.37MCall Options Held
364KPut Options Held
494K-
Vanguard Group Inc Valley Forge, PA466KShares$1.27 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il215KShares$587,5150.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$274,9350.0% of portfolio
-
Geode Capital Management, LLC Boston, MA99.6KShares$271,8090.0% of portfolio
-
Merit Financial Group, LLC98.5KShares$268,9480.01% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $22.3M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...